Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pharmacologic inhibition of 15-prostaglandin dehydrogenase (15-PGDH) increases tissue prostaglandin E2 and accelerates tissue regeneration in multiple organs,…
Amgen will acquire Rodeo Therapeutics in a deal worth up to $721 million, picking up a Seattle-based biotech and its preclinical 15-PGDH inhibitor program. The…
Inflammatory bowel disease (IBD) affects approximately 1.6 million Americans, including approximately 900,000 with ulcerative colitis and 780,000 with Crohn's…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Amgen acquired Seattle-based Rodeo Therapeutics for a $55M upfront payment plus up to $666M in contingent milestone payments (total ~$721M). Rodeo's 15-PGDH program complements Amgen's inflammation portfolio and offers potential applications in tissue regeneration, colitis and IPF.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Rodeo Therapeutics Corporation (this deal) | 2021 | $721M | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
← Browse all deals · How we score deals
More: 2021 deals · Amgen Inc. deals · Immunology deals